Companies: 10,795·Total market cap: $144.5T

NGM Biopharmaceuticals, Inc.

NGM Biopharmaceuticals, Inc.

NGMNASDAQHealthcare

$1.54

$-0.02(-1.28%)

Market Cap$128532096

P/E Ratio—

52W High$4.69

52W Low$0.6002

Avg Volume970K

Open$1.56

Beta1.26

Net Income Financials Revenue

NGM Biopharmaceuticals, Inc. (NGM) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

NGM · net income · updated Jun 9, 2026

Core profitability metrics

NGM · net income · margin · TTM · CAGR

Net income was −$142.4M for FY2023 (fiscal year ending 2023-12-31), up 10.5% year-over-year. Net profit margin was -3223.3%.

FY2023 Net Income−$142.4M▲ +10.5% YoY

Trailing 12M (TTM)—trailing 4 quarters sum

Net Profit Margin< −999%−$142.4M ÷ $4.4M

YoY Change+10.5%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 9, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %

▸ FMP /income-statement · Annual · NGM net income history · NGM profit margin

Annual net income data

NGM · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2023Loss−$142.4M▲ +10.5%-3223.3%$4.4M

FY2022Loss−$159.1M▼ 39.8%-287.5%$55.3M

FY2021Loss−$113.8M▼ 21.1%-146.2%$77.9M

FY2020Loss−$94.0M▼ 229.8%-107.6%$87.4M

FY2019Loss−$28.5M▼ 5680.5%-27.5%$103.5M

Net income vs peers (Healthcare)

NGM vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Johnson & Johnson

$26.80B+90.6%28.5%

Eli Lilly and Company

$20.64B+94.9%31.7%

UnitedHealth Group Incorporated

$12.06B-16.3%2.7%

$4.23B-1.2%6.9%

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

NGM Biopharmaceuticals, Inc. (NGM) reported net income of −$142.4M for FY2023 (fiscal year ending 2023-12-31), up 10.5% year-over-year. The net profit margin was -3223.3% — meaning the company kept $-32.23 of every dollar of revenue as profit.

NGM Biopharmaceuticals, Inc. has not yet achieved annual profitability based on available data (8 fiscal years). The company has reported net losses across all available periods.

NGM Biopharmaceuticals, Inc.'s net profit margin was -3223.3% for FY2023, based on the latest annual results.

Investors sometimes search for "NGM Biopharmaceuticals, Inc. net worth" — the company's market capitalization is a separate figure from NGM net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

NGM net income · 4 questions

NGM Biopharmaceuticals, Inc. is not currently profitable on an annual basis. The company reported a net loss of $142.4M for FY2023.

is NGM profitabledoes NGM make a profitNGM profitabilityNGM profitable company

▸ Source: FMP /income-statement · GAAP · NGM Biopharmaceuticals, Inc. · NGM Biopharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026